Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
45 hedge funds and large institutions have $77.2M invested in Finch Therapeutics Group, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 15 closing their positions.
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
25% more funds holding
Funds holding: 36 → 45 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less capital invested
Capital invested by funds: $109M → $77.2M (-$31.7M)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.19M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$2.52M |
| 3 |
LSCM
Light Street Capital Management
Palo Alto,
California
|
+$2.43M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.03M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$10.3M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.95M |
| 3 |
HM
HealthCor Management
New York
|
-$2.42M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.39M |
| 5 |
MP
MSD Partners
New York
|
-$2.21M |
FNCH Hedge Fund Activity: Q2 2021 in Review
45 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q2 2021, worth a combined $77.2M — down 29% from $109M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new FNCH positions and 15 closed out — a net gain of 9 holders — while 7 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $3.19M. The largest seller was Bank of America, cutting an estimated $10.3M.
- 45 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q2 2021, up from 36 in Q1 2021.
- Funds reported $77.2M of Finch Therapeutics Group, Inc. Common Stock stock for Q2 2021, down 29% quarter-over-quarter.
- 24 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q2 2021 and 15 closed out, a net change of +9 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $3.19M added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q2 2021 was Bank of America, an estimated $10.3M sold.
Based on aggregated 13F filings for Q2 2021.